Gene · 2189
Papers1,427
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,427
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PD-L1+ diffuse large B-cell lymphoma with extremely high mutational burden and microsatellite instability due to acquired PMS2 mutation. | Cold Spring Harb Mol Case Stud | 2023 | 38199780 | PubTator, text mining | PubMed |
| The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic BRCA1 mutations. | Front Oncol | 2023 | 38146508 | PubTator, text mining | PubMed |
| DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. | Pharmaceutics | 2023 | 38140100 | PubTator, text mining | PubMed |
| T cells specific to multiple Bet v 1 peptides are highly cross-reactive toward the corresponding peptides from the homologous group of tree pollens. | Front Immunol | 2023 | 38077382 | PubTator, text mining | PubMed |
| Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. | JCO Precis Oncol | 2023 | 38039432 | PubTator, text mining | PubMed |
| NTHL1 is a recessive cancer susceptibility gene. | Sci Rep | 2023 | 38036545 | PubTator, text mining | PubMed |
| Concepts of multi-level dynamical modelling: understanding mechanisms of squamous cell carcinoma development in Fanconi anemia. | Front Genet | 2023 | 38028610 | PubTator, text mining | PubMed |
| Establishing a novel Fanconi anemia signaling pathway-associated prognostic model and tumor clustering for pediatric acute myeloid leukemia patients. | Open Med (Wars) | 2023 | 38025539 | PubTator, text mining | PubMed |
| Fanconi anemia pathway regulation by FANCI in prostate cancer. | Front Oncol | 2023 | 38023254 | PubTator, text mining | PubMed |
| Pediatric Bone Marrow Failure: A Broad Landscape in Need of Personalized Management. | J Clin Med | 2023 | 38002797 | PubTator, text mining | PubMed |
| Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma. | Biomedicines | 2023 | 38001888 | PubTator, text mining | PubMed |
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. | BMJ Open | 2023 | 37993149 | PubTator, text mining | PubMed |
| Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia. | BMC Med Genomics | 2023 | 37974167 | PubTator, text mining | PubMed |
| Biomarkers in renal cell carcinoma and their targeted therapies: a review. | Explor Target Antitumor Ther | 2023 | 37970211 | PubTator, text mining | PubMed |
| Targeting the DNA Damage Response for Cancer Therapy. | Int J Mol Sci | 2023 | 37958890 | PubTator, text mining | PubMed |
| Construction of iron metabolism-related prognostic features of gastric cancer based on RNA sequencing and TCGA database. | BMC Cancer | 2023 | 37957566 | PubTator, text mining | PubMed |
| DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients. | Diagn Pathol | 2023 | 37924135 | PubTator, text mining | PubMed |
| In silico SNP prediction of selected protein orthologues in insect models for Alzheimer's, Parkinson's, and Huntington's diseases. | Sci Rep | 2023 | 37923901 | PubTator, text mining | PubMed |
| Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. | ESMO Open | 2023 | 37922692 | PubTator, text mining | PubMed |
| Profound DNA methylomic differences between single- and multi-fraction alpha irradiations of lung fibroblasts. | Clin Epigenetics | 2023 | 37891670 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2189/papers?page=3